Provider Briefing: Balsalazide Availability in 2026

If your patients have reported difficulty filling Balsalazide prescriptions, you're hearing a real and recurring complaint. While Balsalazide Disodium is not currently listed on the FDA's drug shortage database, pharmacy-level availability continues to be inconsistent across many markets.

This briefing covers the current supply landscape, prescribing implications, cost and access considerations, and practical tools you can use to help patients maintain continuity of care.

Current Supply Timeline

Balsalazide Disodium — available as 750 mg capsules (generic and brand Colazal) and 1.1 g tablets (Giazo) — has not been subject to a formal FDA shortage listing in recent years. Generic production continues from manufacturers including Apotex and Mylan.

However, Balsalazide's relatively low prescribing volume compared to other aminosalicylates creates a persistent availability gap at the retail pharmacy level. This is not a manufacturing shortage but rather a stocking and distribution challenge:

• Chain pharmacies may not routinely stock Balsalazide due to low turnover
• Automated inventory systems deprioritize infrequently dispensed medications
• The small number of generic manufacturers makes the supply chain more fragile

The result is a pattern familiar to prescribers of other niche generics: the drug is available in the supply chain, but individual patients face delays or stockouts at their preferred pharmacy.

Prescribing Implications

Balsalazide remains a viable first-line aminosalicylate for mild to moderately active ulcerative colitis in adults and children (ages 5+). The American College of Gastroenterology recommends 5-ASA therapy as initial treatment, and Balsalazide's colon-targeted delivery offers advantages for patients who need high concentrations of mesalamine in the large intestine.

Key prescribing considerations in the current environment:

For New Prescriptions

• Consider whether Balsalazide's specific delivery profile (colon-targeted via azo-bond cleavage) is clinically necessary, or whether a more widely available mesalamine formulation would be equivalent for the patient
• If prescribing Balsalazide, advise the patient to call their pharmacy to confirm availability before their appointment ends
• Write the prescription for the generic (balsalazide disodium) to maximize pharmacy flexibility

For Existing Patients

• Patients stable on Balsalazide should not be switched unnecessarily — but having a documented backup plan is prudent
• Discuss alternative aminosalicylates proactively so patients know what to do if they can't fill their Balsalazide
• Encourage patients to use Medfinder for Providers to locate pharmacies with current stock

Availability Picture

Based on pharmacy-level data and patient reports, Balsalazide availability varies significantly by region and pharmacy type:

• Chain pharmacies (CVS, Walgreens, Rite Aid): Inconsistent stocking. Many locations do not carry Balsalazide routinely and require special orders.
• Independent pharmacies: Generally more willing and able to order from multiple wholesalers. Turnaround is typically 24-48 hours.
• Mail-order pharmacies: Generally reliable stock due to larger centralized inventories.
• Specialty pharmacies: Not typically needed for Balsalazide, but may be an option for patients with complex regimens.

Cost and Access

Cost can be a significant barrier, particularly for uninsured or underinsured patients:

• Generic Balsalazide retail price: $350-$430/month (270 capsules at 750 mg)
• With discount coupon (GoodRx, SingleCare): $80-$100/month
• Sulfasalazine (alternative): $10-$30/month — significantly cheaper
• Generic Mesalamine: $50-$150/month with coupons

Insurance coverage for generic Balsalazide is generally favorable (Tier 2 or 3 on most formularies), with prior authorization uncommon. Brand-name Colazal and Giazo may face step therapy requirements.

No active manufacturer copay card programs exist for generic Balsalazide. Prescription Hope offers Colazal and Giazo at $70/month for qualifying patients through their patient assistance program. NeedyMeds and RxAssist maintain updated directories of assistance programs.

For patient-facing cost information, see how to save money on Balsalazide.

Tools and Resources for Providers

Several tools can help you and your care team support patients who are having trouble finding Balsalazide:

Medfinder for Providers

Medfinder allows providers and care teams to search for pharmacies that have specific medications in stock. This can be integrated into your prescribing workflow to verify availability before the patient leaves the office.

Drug Interaction Considerations

When prescribing Balsalazide alongside other medications, keep these interactions in mind:

• Azathioprine / 6-Mercaptopurine: Balsalazide (via its mesalamine metabolite) can inhibit thiopurine methyltransferase (TPMT), increasing thioguanine nucleotide levels and risk of myelosuppression. Monitor CBC regularly.
• NSAIDs: Concomitant use increases nephrotoxicity risk. Monitor renal function.
• Nephrotoxic agents: Use caution and monitor renal function when combining with other nephrotoxic drugs.

For detailed interaction information, see Balsalazide drug interactions.

Alternative Prescribing Quick Reference

If switching a patient from Balsalazide, consider these 5-ASA alternatives:

• Mesalamine delayed-release (Asacol HD, Delzicol): Most direct alternative; colon-targeted delivery
• Mesalamine extended-release (Pentasa): Releases throughout the GI tract; useful for more proximal disease
• Mesalamine MMX (Lialda): Once-daily dosing; good for adherence
• Sulfasalazine (Azulfidine): Most affordable; ~20% intolerance rate due to sulfapyridine
• Mesalamine rectal (Rowasa, Canasa): For distal/left-sided disease; can combine with oral therapy

More details: alternatives to Balsalazide.

Looking Ahead

The availability situation for Balsalazide is unlikely to change dramatically in 2026 absent new generic entrants or significant changes in prescribing patterns. The fundamental challenge — low volume leading to inconsistent stocking — is structural.

Providers can help by:

1. Incorporating pharmacy availability checks into the prescribing workflow
2. Proactively discussing backup alternatives with patients
3. Recommending tools like Medfinder to patients and staff
4. Considering whether a more widely available 5-ASA formulation meets the patient's clinical needs

Final Thoughts

Balsalazide remains an effective and well-tolerated aminosalicylate for ulcerative colitis, but its niche market position creates real access challenges for patients. As prescribers, the most impactful steps we can take are ensuring patients have a backup plan, verifying pharmacy availability at the point of prescribing, and leveraging tools that connect patients with pharmacies that have their medication in stock.

For provider tools and resources, visit Medfinder for Providers.